|
1
|
Bijlsma JW, Berenbaum F and Lafeber FP:
Osteoarthritis: an update with relevance for clinical practice.
Lancet. 377:2115–2126. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang L, Rong J, Zhang Q, et al:
Prevalence and associated factors of knee osteoarthritis in a
community-based population in Heilongjiang. Northeast China.
Rheumatol Int. 32:1189–1195. 2012. View Article : Google Scholar
|
|
3
|
Bobacz K, Erlacher L, Smolen J, Soleiman A
and Graninger WB: Chondrocyte number and proteoglycan synthesis in
the aging and osteoarthritic human articular cartilage. Ann Rheum
Dis. 63:1618–1622. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yatabe T, Mochizuki S, Takizawa M, et al:
Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human
osteoarthritic chondrocytes. Ann Rheum Dis. 68:1051–1058. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheung KS, Hashimoto K, Yamada N and Roach
HI: Expression of ADAMTS-4 by chondrocytes in the surface zone of
human osteoarthritic cartilage is regulated by epigenetic DNA
de-methylation. Rheumatol Int. 29:525–534. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Larsson S, Englund M, Struglics A and
Lohmander LS: Association between synovial fluid levels of aggrecan
ARGS fragments and radiographic progression in knee osteoarthritis.
Arthritis Res Ther. 12:R2302010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang K and Wu LD: Suppression of
aggrecanase: a novel protective mechanism of dehydroepiandrosterone
in osteoarthritis? Mol Biol Rep. 37:1241–1245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Naito S, Shiomi T, Okada A, et al:
Expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic
cartilage. Pathol Int. 57:703–711. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Verma P and Dalal K: ADAMTS-4 and
ADAMTS-5: key enzymes in osteoarthritis. J Cell Biochem.
112:3507–3514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matsui Y, Iwasaki N, Kon S, et al:
Accelerated development of aging-associated and instability-induced
osteoarthritis in osteopontin-deficient mice. Arthritis Rheum.
60:2362–2371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pullig O, Weseloh G, Gauer S and Swoboda
B: Osteopontin is expressed by adult human osteoarthritic
chondrocytes: protein and mRNA analysis of normal and
osteoarthritic cartilage. Matrix Biol. 19:245–255. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao SG, Li KH, Zeng KB, Tu M, Xu M and Lei
GH: Elevated osteopontin level of synovial fluid and articular
cartilage is associated with disease severity in knee
osteoarthritis patients. Osteoarthritis Cartilage. 18:82–87. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sharif SA, Du X, Myles T, et al:
Thrombin-activatable carboxypeptidase B cleavage of osteopontin
regulates neutrophil survival and synoviocyte binding in rheumatoid
arthritis. Arthritis Rheum. 60:2902–2912. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kon S, Ikesue M, Kimura C, et al:
Syndecan-4 protects against osteopontin-mediated acute hepatic
injury by masking functional domains of osteopontin. J Exp Med.
205:25–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Altman R, Asch E, Bloch D, et al:
Development of criteria for the classification and reporting of
osteoarthritis. Classification of osteoarthritis of the knee.
Diagnostic and Therapeutic Criteria Committee of the American
Rheumatism Association. Arthritis Rheum. 29:1039–1049. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM
and Lee FY: Elevated plasma osteopontin level is associated with
occurrence of psoriasis and is an unfavorable cardiovascular risk
factor in patients with psoriasis. J Am Acad Dermatol. 60:225–230.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Denhardt DT, Giachelli CM and Rittling SR:
Role of osteopontin in cellular signaling and toxicant injury. Annu
Rev Pharmacol Toxicol. 41:723–749. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ramaiah SK and Rittling S: Role of
osteopontin in regulating hepatic inflammatory responses and toxic
liver injury. Expert Opin Drug Metab Toxicol. 3:519–526. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ermakov S, Leonov A, Trofimov S, Malkin I
and Livshits G: Quantitative genetic study of the circulating
osteopontin in community-selected families. Osteoporos Int.
22:2261–2271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Glasson SS, Askew R, Sheppard B, et al:
Deletion of active ADAMTS5 prevents cartilage degradation in a
murine model of osteoarthritis. Nature. 434:644–648. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stanton H, Rogerson FM, East CJ, et al:
ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in
vitro. Nature. 434:648–652. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koshy PJ, Lundy CJ, Rowan AD, et al: The
modulation of matrix metalloproteinase and ADAM gene expression in
human chondrocytes by interleukin-1 and oncostatin M: a time-course
study using real-time quantitative reverse transcription-polymerase
chain reaction. Arthritis Rheum. 46:961–967. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moulharat N, Lesur C, Thomas M, et al:
Effects of transforming growth factor-beta on aggrecanase
production and proteoglycan degradation by human chondrocytes in
vitro. Osteoarthritis Cartilage. 12:296–305. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hui W, Barksby HE, Young DA, et al:
Oncostatin M in combination with tumour necrosis factor alpha
induces a chondrocyte membrane-associated aggrecanase that is
distinct from ADAMTS aggrecanase-1 or-2. Ann Rheum Dis.
64:1624–1632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tortorella MD, Malfait AM, Deccico C and
Arner E: The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5
(aggrecanase-2) in a model of cartilage degradation. Osteoarthritis
Cartilage. 9:539–552. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ohshima S, Yamaguchi N, Nishioka K, et al:
Enhanced local production of osteopontin in rheumatoid joints. J
Rheumatol. 29:2061–2067. 2002.PubMed/NCBI
|
|
27
|
Petrow PK, Hummel KM, Schedel J, et al:
Expression of osteopontin messenger RNA and protein in rheumatoid
arthritis: effects of osteopontin on the release of collagenase 1
from articular chondrocytes and synovial fibroblasts. Arthritis
Rheum. 43:1597–1605. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Standal T, Borset M and Sundan A: Role of
osteopontin in adhesion, migration, cell survival and bone
remodeling. Exp Oncol. 26:179–184. 2004.PubMed/NCBI
|
|
29
|
Attur MG, Dave MN, Stuchin S, Kowalski AJ,
Steiner G, Abramson SB, Denhardt DT and Amin AR: Osteopontin: An
intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum.
44:578–584. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu G, Nie H, Li N, et al: Role of
osteopontin in amplification and perpetuation of rheumatoid
synovitis. J Clin Invest. 115:1060–1067. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Okamura N, Hasegawa M, Nakoshi Y, et al:
Deficiency of tenascin-C delays articular cartilage repair in mice.
Osteoarthritis Cartilage. 18:839–848. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakoshi Y, Hasegawa M, Akeda K, Iino T,
Sudo A, Yoshida T and Uchida A: Distribution and role of tenascin-C
in human osteoarthritic cartilage. J Orthop Sci. 15:666–673. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao SG, Cheng L, Zeng C, et al: Usefulness
of specific OA biomarkers, thrombin-cleaved osteopontin, in the
posterior cruciate ligament OA rabbit model. Osteoarthritis
Cartilage. 21:144–150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cook AC, Chambers AF, Turley EA and Tuck
AB: Osteopontin induction of hyaluronan synthase 2 expression
promotes breast cancer malignancy. J Biol Chem. 281:24381–24389.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tajima K, Ohashi R, Sekido Y, Hida T, Nara
T, Hashimoto M, Iwakami S, Minakata K, Yae T, Takahashi F, et al:
Osteopontin-mediated enhanced hyaluronan binding induces multidrug
resistance in mesothelioma cells. Oncogene. 29:1941–1951. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ariyoshi W, Takahashi N, Hida D, Knudson
CB and Knudson W: Mechanisms involved in enhancement of the
expression and function of aggrecanases by hyaluronan
oligosaccharides. Arthritis Rheum. 64:187–197. 2012. View Article : Google Scholar : PubMed/NCBI
|
